Clinical Trials
52 trialsNCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04489173 2026-05-22
TIBET
Borstkanker Onderzoek Groep
Phase 2 Completed
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT04868773 2026-04-24
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
Phase 1 Completed
NCT07492173 2026-03-25
Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans
Shandong New Time Pharmaceutical Co., LTD
Phase NA Completed
NCT03223779 2026-03-12
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT03686488 2026-03-02
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04109924 2026-02-10
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Phase 2 Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04457297 2026-01-21
ALTAIR
National Cancer Center Hospital East
Phase 3 Completed
NCT04417699 2025-12-10
SHORT
Providence Health & Services
Phase 2 Completed
NCT05600309 2025-11-26
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT04923529 2025-07-18
TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
The University of Hong Kong
Phase 2 Completed
NCT04393298 2025-05-29
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Pharma
Phase 1/2 Completed
NCT05481463 2025-05-28
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sun Yat-sen University
Phase 2 Completed
NCT02261532 2024-11-14
A Phase I Study of TAS-102 in Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04737187 2024-09-24
SUNLIGHT
Taiho Oncology, Inc.
Phase 3 Completed
NCT01607957 2024-09-19
RECOURSE
Taiho Oncology, Inc.
Phase 3 Completed
NCT01867866 2024-09-05
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Taiho Oncology, Inc.
Phase 1 Completed
NCT01867879 2024-09-05
Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT01874522 2024-09-05
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Taiho Oncology, Inc.
Phase 1 Completed
NCT01916447 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Taiho Oncology, Inc.
Phase 1 Completed
NCT02031055 2024-09-05
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT02301104 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT02301117 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT02500043 2024-09-03
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Taiho Oncology, Inc.
Phase 3 Completed
NCT02860546 2024-09-03
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
Taiho Oncology, Inc.
Phase 2 Completed
NCT03981614 2024-08-22
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT05130060 2024-08-14
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
Mayo Clinic
Phase 1 Completed
NCT03520946 2024-08-09
RAMTAS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3 Completed
NCT03274882 2024-07-25
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
Servier
Phase 2 Completed
NCT03317119 2024-04-08
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
City of Hope Medical Center
Phase 1 Completed
NCT04074343 2024-02-02
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
Phase 1 Completed
NCT05468892 2024-02-01
VELO
University of Campania Luigi Vanvitelli
Phase 2 Completed
NCT03810742 2023-11-18
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
Phase 1 Completed
NCT06031376 2023-09-11
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Completed
NCT04072445 2023-08-09
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
Phase 2 Completed
NCT03278106 2023-06-28
TAS-102 in Treating Advanced Biliary Tract Cancers
Mayo Clinic
Phase 2 Completed
NCT05869097 2023-05-22
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT03297710 2023-01-05
TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery
Mayo Clinic
Phase 1 Completed
NCT03616574 2022-09-21
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Holy Stone Healthcare Co., Ltd
Phase 1 Completed
NCT02602327 2022-08-01
Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
University of California, San Francisco
Phase 1 Completed
NCT02920476 2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2 Completed
NCT03974594 2022-04-19
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT03799731 2022-04-14
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
GamaMabs Pharma
Phase 2 Completed
NCT04965870 2022-03-07
RETRO-TAS
Hellenic Study Group of Psychoneuroimmunology in Cancer
Completed
NCT03305913 2021-03-26
REMETY
AIO-Studien-gGmbH
Phase 1 Completed
NCT01955837 2020-11-17
TERRA
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed